Molecular Subtype
Myeloproliferative Neoplasm, BCR-ABL1 Negative
CI-CAN-00003386Explore in graph →
Hematologic94 active trials2 approved drugs8 evidence items
- NCIt
- C198555
Loading cancer entity…
Molecular Subtype
CI-CAN-00003386Explore in graph →
Clinical trials
333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03560752 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | active not recruiting | Phase 1 | 34 | City of Hope Medical CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05025488 | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 7 | Marina KremyanskayaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | recruiting | Phase 1 / Phase 2 | 150 | Disc Medicine, IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT02530034 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07469891 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | recruiting | Phase 1 | 100 | Prelude Therapeutics IncorporatedINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07012109 | Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) | recruiting | Phase 1 | 90 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07302776 | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | recruiting | Phase 1 | 50 | Stanford UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | recruiting | Phase 1 | 46 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07250646 | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | recruiting | Phase 1 | 28 | Aspera Biomedicines, Inc.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05233618 | Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) | active not recruiting | Phase 1 | 44 | Karen Ballen, MDOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07128381 | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | recruiting | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT07612280 | Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis | recruiting | Phase 1 / Phase 2 | 30 | Jubilant Therapeutics Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07379125 | Therapeutic RSK1 Targeting in Myelofibrosis | recruiting | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04817007 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | active not recruiting | Phase 1 / Phase 2 | 216 | Bristol-Myers SquibbINDUSTRY | 11 | May 8, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07529951 | Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers | not yet recruiting | Phase 1 | 60 | Eilean TherapeuticsINDUSTRY | 0 | Apr 14, 2026 | clinicaltrials |
| NCT06047886 | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy | recruiting | Phase 1 | 50 | University of Alabama at BirminghamOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04279847 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms(LIMBER) | active not recruiting | Phase 1 | 140 | Incyte CorporationINDUSTRY | 8 | Apr 1, 2026 | clinicaltrials |
| NCT05123365 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 27 | University of California, IrvineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | active not recruiting | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03912064 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | active not recruiting | Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03326310 | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | recruiting | Phase 1 | 18 | University of ChicagoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera(SLN) | active not recruiting | Phase 1 / Phase 2 | 69 | Silence Therapeutics plcINDUSTRY | 9 | Dec 19, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06378437 | A Study of GLB-001 in Patients With Myeloid Malignancies | recruiting | Phase 1 | 108 | Hangzhou GluBio Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04454658 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 14 | Jul 16, 2025 | clinicaltrials |
| NCT06752746 | A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | recruiting | Phase 1 | 108 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs(TREG108) | recruiting | Phase 1 | 24 | Cellenkos, Inc.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | recruiting | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials